369 related articles for article (PubMed ID: 21251615)
1. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.
Wilson NS; Yang B; Yang A; Loeser S; Marsters S; Lawrence D; Li Y; Pitti R; Totpal K; Yee S; Ross S; Vernes JM; Lu Y; Adams C; Offringa R; Kelley B; Hymowitz S; Daniel D; Meng G; Ashkenazi A
Cancer Cell; 2011 Jan; 19(1):101-13. PubMed ID: 21251615
[TBL] [Abstract][Full Text] [Related]
2. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
[TBL] [Abstract][Full Text] [Related]
3. Development of a bioassay as a measure of drozitumab-mediated apoptosis induced by soluble Fc gamma receptors.
Shim J; Huang A; Miller AS
J Immunol Methods; 2017 Sep; 448():26-33. PubMed ID: 28506821
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
Li F; Ravetch JV
Science; 2011 Aug; 333(6045):1030-4. PubMed ID: 21852502
[TBL] [Abstract][Full Text] [Related]
5. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
Richman LP; Vonderheide RH
Cancer Immunol Res; 2014 Jan; 2(1):19-26. PubMed ID: 24416732
[TBL] [Abstract][Full Text] [Related]
6. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
7. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.
Gieffers C; Kluge M; Merz C; Sykora J; Thiemann M; Schaal R; Fischer C; Branschädel M; Abhari BA; Hohenberger P; Fulda S; Fricke H; Hill O
Mol Cancer Ther; 2013 Dec; 12(12):2735-47. PubMed ID: 24101228
[TBL] [Abstract][Full Text] [Related]
8. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
[TBL] [Abstract][Full Text] [Related]
9. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement.
Li F; Ravetch JV
Proc Natl Acad Sci U S A; 2012 Jul; 109(27):10966-71. PubMed ID: 22723355
[TBL] [Abstract][Full Text] [Related]
10. Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.
Waight JD; Chand D; Dietrich S; Gombos R; Horn T; Gonzalez AM; Manrique M; Swiech L; Morin B; Brittsan C; Tanne A; Akpeng B; Croker BA; Buell JS; Stein R; Savitsky DA; Wilson NS
Cancer Cell; 2018 Jun; 33(6):1033-1047.e5. PubMed ID: 29894690
[TBL] [Abstract][Full Text] [Related]
11. Analysis of FcγR-Dependent Agonism of Antibodies Specific for Receptors of the Tumor Necrosis Factor (TNF) Receptor Superfamily (TNFRSF).
Medler J; Wajant H
Methods Mol Biol; 2021; 2248():81-90. PubMed ID: 33185869
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
13. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates.
Zalevsky J; Leung IW; Karki S; Chu SY; Zhukovsky EA; Desjarlais JR; Carmichael DF; Lawrence CE
Blood; 2009 Apr; 113(16):3735-43. PubMed ID: 19109559
[TBL] [Abstract][Full Text] [Related]
14. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
15. FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
White AL; Chan HT; French RR; Beers SA; Cragg MS; Johnson PW; Glennie MJ
Cancer Immunol Immunother; 2013 May; 62(5):941-8. PubMed ID: 23543215
[TBL] [Abstract][Full Text] [Related]
16. A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo.
Lei G; Xu M; Xu Z; Gu L; Lu C; Bai Z; Wang Y; Zhang Y; Hu H; Jiang Y; Zhao W; Tan S
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28953230
[TBL] [Abstract][Full Text] [Related]
17. Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility.
Liu X; Zhao Y; Shi H; Zhang Y; Yin X; Liu M; Zhang H; He Y; Lu B; Jin T; Li F
Nat Commun; 2019 Sep; 10(1):4206. PubMed ID: 31562320
[TBL] [Abstract][Full Text] [Related]
18. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.
Huet HA; Growney JD; Johnson JA; Li J; Bilic S; Ostrom L; Zafari M; Kowal C; Yang G; Royo A; Jensen M; Dombrecht B; Meerschaert KR; Kolkman JA; Cromie KD; Mosher R; Gao H; Schuller A; Isaacs R; Sellers WR; Ettenberg SA
MAbs; 2014; 6(6):1560-70. PubMed ID: 25484045
[TBL] [Abstract][Full Text] [Related]
19. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
20. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors.
Haynes NM; Hawkins ED; Li M; McLaughlin NM; Hämmerling GJ; Schwendener R; Winoto A; Wensky A; Yagita H; Takeda K; Kershaw MH; Darcy PK; Smyth MJ
J Immunol; 2010 Jul; 185(1):532-41. PubMed ID: 20505139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
